Skip to content
2000
Volume 11, Issue 7
  • ISSN: 1570-1808
  • E-ISSN: 1875-628X

Abstract

The high toxicity and the growing resistance are the major drawbacks of available antileishmanials. Our previous in vitro studies have identified oxabicyclo[3.3.1]nonanones as antileishmanial agents that act on the redox enzymes of the parasite. In the current study, antileishmanial activity of 4-(4,4,8-trimethyl-7-oxo-3-oxabicyclo[3.3.1]non-2-yl)- benzoic acid methyl ester (PS 203) the most potent oxabicyclo[3.3.1]nonanone identified in our previous study is evaluated using the hamster model. There was 77.29 ± 3.0 % inhibition of parasite growth observed after a 5-day treatment of 5 mg/kg body weight dose. Further, the in vivo toxicity study of the compound in Swiss albino mice revealed no hepatic or renal toxicity.

Loading

Article metrics loading...

/content/journals/lddd/10.2174/1570180811666140423203826
2014-08-01
2025-07-04
Loading full text...

Full text loading...

/content/journals/lddd/10.2174/1570180811666140423203826
Loading

  • Article Type:
    Research Article
Keyword(s): Drug design; In vivo assessment; Leishmaniasis; Oxabicyclo[3.3.1]nonanones; Toxicity
This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error
Please enter a valid_number test